Loading...
Loading...
Of the 2 tracked institutions holding BRNS, 2 have a 3-year clone track record — 2 of them beat the S&P. Average holder's clone alpha: +6.5pt. It's a gauge of who owns the name, not just how many.
Alpha = the manager's 3-year clone return minus the S&P 500. A skilled roster is a stronger tell than a crowded one — though even skilled managers' edge doesn't reliably survive the 13F disclosure lag. Why →
Among the 2 tracked institutional investors we monitor, BRNS (BARINTHUS BIOTHERAPEUTICS PL) is held with a combined value of $67.16K across 101,754 shares. The largest holder is CITADEL ADVISORS LLC with a position worth $50.66K. 2 funds reduced their position.
Total Institutional Value
$67.16K
Total Shares Held
101,754
Institutional Holders
2
Ranked by estimated dollars moved (share change × implied price). 13F data lags up to 45 days.
None this quarter.
| # | Fund | Value↓ | Portfolio % | Change |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | $50.66K | 0.00% | -35.5% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | $16.50K | 0.00% | -83.4% |
SEC Schedule 13D (activist) and 13G (passive) filings for BRNS. Filed when an investor acquires 5%+ ownership.
As of the latest SEC 13F filings, CITADEL ADVISORS LLC is the largest institutional holder of BRNS with a position worth $50.66K, representing 0.00% of their portfolio. In total, 2 institutional investors hold BRNS with a combined value of $67.16K.
Institutional investors hold $67.16K worth of BRNS stock across 2 positions. The largest institutional holder is CITADEL ADVISORS LLC with $50.66K in holdings.
A 13F filing is a quarterly report required by the SEC from institutional investment managers with over $100 million in assets. It discloses their holdings in U.S. equities. For BRNS, these filings reveal which major funds are accumulating or reducing positions, providing insights into institutional sentiment.
Get notified when hedge funds change their BRNS positions.
